Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: A retrospective chart review

Journal of Clinical Psychiatry

Volumn 68, Issue 1, 2007, Pages 22-28

  Goethe, John W ^a,b   Szarek, Bonnie L ^a   Caley, Charles F ^a   Woolley, Stephen B ^a  

^a INSTITUTE OF LIVING   (United States)

^b Burlingame Ctr Psychiat Res/Educ   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; HIGH DENSITY LIPOPROTEIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GLUCOSE ASSAY; HOSPITAL PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SYMPTOMATOLOGY;

EID: 33846853948     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0103     Document Type: Article

References (52)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65:267-272
3. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716
4. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 2004;53(suppl 1):S152-S158
5. Hunt KJ, Resendez RG, Williams K, et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004;110:1251-1257
6. Wilson PW. Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view. Endocrinol Metab Clin North Am 2004; 33:467-481
7. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-342I
8. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, pt 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553
9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359
10. Gupta S, Steinmeyer C, Frank B, et al. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Ther 2003;10:348-355
11. Paton C, Esop R, Young C, et al. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004;110:299-305
12. Sernyak MJ, Gulanski B, Rosenheck R. Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. J Clin Psychiatry 2005;66: 1463-1467
13. McEvoy JP, Meyer MJ, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates for NHANESIII. Schizophr Res 2005;80:19-32
14. Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-579
15. Dixon LB, Kreyenbuhl JA, Dickerson FB, et al. A comparison of type 2 diabetes outcomes among persons with and without severe mental illness. Psychiatr Serv 2004;55:892-900
16. Goethe JW, Szarek BL, Caley CF. Metabolic syndrome in psychiatric inpatients taking antipsychotics. Presented at the 158th annual meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, Ga
17. Botvinik L, Ng C, Schweitzer I, Audit of antipsychotic prescribing in a private psychiatric hospital. Australas Psychiatry 2004;12:227-233
18. Barbui C, Ciuna A, Nose M, et al. Off-label and non-classical prescriptions of antipsychotic agents in ordinary inpatient practice. Acta Psychiatr Scand 2004;109:275-278
19. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65(suppl 7):4-18
20. Moretensen PB, Juel K. Mortality and causes of death in first admitted schizophrenia patients. Br J Psychiatry 1993;163:183-189
21. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-217
22. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45: 21-28
23. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-220
24. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998;338:1516-1520
25. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001;21:369-374
26. Sernyak MJ, Lesllie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566
27. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243
28. Dixon L, Postrado L, Delahanty J, et al. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999;187:496-502
29. Ananth J, Venkatesh R, Burgoyne K, et al. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002;71:244-254
30. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal. Diabetes Care 2005;28:2289-2304
31. Pappadopulos E, Jensen PS, Schur SB, et al. "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophr Bull 2002;28:111-121
32. Van Brunt DL, Gibson PJ, Ramsey JL, et al. Outpatient use of major antipsychotic drugs in ambulatory care settings in the United States, 1997-2000. MedGenMed 2003;5:16
33. Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004; 24(5 suppl 1):S1-S6
34. Saad MF, Rewers M, Selby J, et al. Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis Study. Hypertension 2004;43: 1324-1331
35. Citrome L, Jaffe A, Levine J, et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004;55:1006-1013
36. Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999;156:1270-1272
37. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856-865
38. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl 2004;47:S76-S79
39. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry 2003;160:284-289
40. Bushe C, Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl 2004;47:S67-S71
41. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997;171:502-508
42. Braceland FJ, Meduna LH, Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry 1945;102:108-110
43. Freeman H. Resistance to insulin in mentally disturbed soldiers. Arch Neurol Psychiatry 1946;56:74-78
44. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989;1:495
45. Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat 10 1995:1-260
46. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996;37:68-73
47. Keskiner A, el-Toumi A, Bosquet T. Psychotropic drugs, diabetes, and chronic mental patients. Psychosomatics 1973;14:176-181
48. Bowden CL. Valproate. Bipolar Disord 2003;5:189-202
49. Cassano P, Fava M. Tolerability issues during long-term treatment with antidepressants. Ann Clin Psychiatry 2004;16:15-25
50. Schwartz TL, Nihalani N, Jindal S, et al. Psychiatric medication-induced obesity: a review. Obes Rev 2004;5:115-121
51. Rothman KJ. Modern Epidemiology. Boston, Mass: Little, Brown & Co: 1986
52. Taylor D, Young C, Esop R, et al. Testing for diabetes in hospitalized patients prescribed antipsychotic drugs. Br J Psychiatry 2004;185:152-156